← Back to Analyst Consensus 
RARE Buy
Ultragenyx Pharmaceutical Inc.
Current Price —
Implied Upside —
Analysts 26
30-Day Momentum
▲ 1 upgrades / ▼ 0 downgrades / 0 reiterations from 1 firms
Next Earnings
Nov 4, 2026 (8 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 15, 2026 | UBS | initiate | — → Neutral | — | 54% |
| Sep 21, 2026 | Evercore ISI Group | maintain | In-Line → In-Line | — | 58% |
| Sep 21, 2026 | Barclays | maintain | Overweight → Overweight | — | 53% |
| Sep 18, 2026 | Morgan Stanley | maintain | Equal-Weight → Equal-Weight | — | 54% |
| Sep 18, 2026 | Citigroup | maintain | Buy → Buy | — | 54% |
| Sep 18, 2026 | Canaccord Genuity | maintain | Buy → Buy | — | 48% |
| Sep 18, 2026 | Cantor Fitzgerald | maintain | Overweight → Overweight | — | 50% |
| Sep 17, 2026 | Citigroup | maintain | Buy → Buy | — | 54% |
| Sep 4, 2026 | Goldman Sachs | maintain | Neutral → Neutral | — | 54% |
| Sep 4, 2026 | Barclays | maintain | Overweight → Overweight | — | 53% |
| Sep 3, 2026 | JP Morgan | downgrade | Overweight → Neutral | — | 55% |
| Sep 3, 2026 | Jefferies | maintain | Buy → Buy | — | 52% |
| Sep 3, 2026 | William Blair | downgrade | Outperform → Market Perform | — | 48% |
| Sep 3, 2026 | Citigroup | maintain | Buy → Buy | — | 54% |
| Sep 3, 2026 | TD Cowen | maintain | Buy → Buy | — | 54% |
| Sep 3, 2026 | Wells Fargo | maintain | Overweight → Overweight | — | 54% |
| Sep 3, 2026 | Canaccord Genuity | maintain | Buy → Buy | — | 48% |
| Sep 3, 2026 | Wedbush | maintain | Neutral → Neutral | — | 58% |
| Sep 3, 2026 | Evercore ISI Group | downgrade | Outperform → In-Line | — | 58% |
| Sep 3, 2026 | Baird | downgrade | Outperform → Neutral | — | 55% |
| Sep 3, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Sep 3, 2026 | Cantor Fitzgerald | maintain | Overweight → Overweight | — | 50% |
| Aug 28, 2026 | Wells Fargo | maintain | Overweight → Overweight | — | 54% |
| Aug 25, 2026 | JP Morgan | maintain | Overweight → Overweight | — | 55% |
| Aug 21, 2026 | Morgan Stanley | maintain | Overweight → Overweight | — | 54% |
| Aug 20, 2026 | Canaccord Genuity | maintain | Buy → Buy | — | 48% |
| Aug 20, 2026 | Citigroup | maintain | Buy → Buy | — | 54% |
| Aug 20, 2026 | Wells Fargo | maintain | Overweight → Overweight | — | 54% |
| Aug 20, 2026 | Cantor Fitzgerald | maintain | Overweight → Overweight | — | 50% |
| Aug 10, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Aug 5, 2026 | Wells Fargo | maintain | Overweight → Overweight | — | 54% |
| Aug 4, 2026 | Guggenheim | maintain | Buy → Buy | — | 52% |
| Jul 7, 2026 | RBC Capital | maintain | Outperform → Outperform | — | 55% |
| May 21, 2026 | Cantor Fitzgerald | maintain | Overweight → Overweight | — | 50% |
| May 8, 2026 | Wedbush | maintain | Neutral → Neutral | — | 58% |
| May 8, 2026 | Guggenheim | maintain | Buy → Buy | — | 52% |
| May 6, 2026 | Wells Fargo | maintain | Overweight → Overweight | — | 54% |
| May 6, 2026 | Wedbush | maintain | Neutral → Neutral | — | 58% |
| Apr 29, 2026 | Barclays | maintain | Overweight → Overweight | — | 53% |
| Oct 22, 2024 | Cantor Fitzgerald | reiterate | Overweight → Overweight | $116 | 50% |
| Oct 21, 2024 | TD Cowen | maintain | Buy → Buy | $73 | 54% |
| Oct 1, 2024 | Cantor Fitzgerald | reiterate | Overweight → Overweight | $116 | 50% |
| Sep 26, 2024 | RBC Capital | reiterate | Outperform → Outperform | $77 | 55% |
| Sep 20, 2024 | Cantor Fitzgerald | reiterate | Overweight → Overweight | $116 | 50% |
| Sep 16, 2024 | Cantor Fitzgerald | reiterate | Overweight → Overweight | $116 | 50% |
| Aug 5, 2024 | Barclays | maintain | Overweight → Overweight | $81 | 53% |
| Aug 2, 2024 | Wells Fargo | maintain | Overweight → Overweight | $75 | 54% |
| Aug 2, 2024 | Goldman Sachs | maintain | Buy → Buy | $76 | 54% |
| Aug 2, 2024 | Cantor Fitzgerald | maintain | Overweight → Overweight | $116 | 50% |
| Aug 2, 2024 | Wedbush | maintain | Neutral → Neutral | $46 | 58% |
Price Target Trend
Jul 31, 2026 Latest: $26.25 Oct 26, 2026
EPS Estimates
0y $-4.08
Lo: $-4.96 Hi: $-1.18
6 analysts +1q $-0.66
Lo: $-1.08 Hi: $0.78
6 analysts 0q $-0.75
Lo: $-1.25 Hi: $0.75
6 analysts +1y $0.23
Lo: $-1.69 Hi: $4.50
6 analysts Cross-Platform Signals
No cross-platform signals in the last 90 days